化滞柔肝颗粒治疗非酒精性脂肪性肝病疗效观察-论文.pdf

《化滞柔肝颗粒治疗非酒精性脂肪性肝病疗效观察-论文.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、·2302·现代中西医结合杂志ModernJournalofIntegratedTraditionalChineseandWesternMedicine2014Jul，23(21)化滞柔肝颗粒治疗非酒精性脂肪性肝病疗效观察于洋，钱丽旗，侯鹏，武冰，李素那，任金涛(解放军总医院第一附属医院，北京100048)[摘要】目的观察化滞柔肝颗粒治疗非酒精性脂肪性肝病(NAFLD)的临床疗效。方法将6O例NAFLD患者随机分为2组，对照组30例1：2服水飞蓟宾葡甲胺片，治疗组30例口服化滞柔肝颗粒，2组均治疗12周。比较2组患者治疗前后症状积分、血清肝酶、血脂、体质量指数和肝脏B

2、超分度情况。结果治疗组总有效率为87％，对照组为67％，2组比较差异有统计学意义(P<0．05)；治疗组症状积分、体质量指数、血脂和肝脏B超分度改善情况均明显优于对照组(P均<0．05)；2组治疗后肝功能均有改善，但组间比较差异无统计学意义(P>0．05)。结论化滞柔肝颗粒治疗NAFLD疗效较好，其疗效机制有待进一步探讨。[关键词]非酒精性脂肪性肝病；化滞柔肝颗粒；水飞蓟宾葡甲胺片doi：10．3969／j．issn．1008—8849．2Ol4．21．008[中图分类号]R575．5[文献标识码]A[文章编号]1008—8849(2014)21—2302一O3Obs

3、ervationofHuazhiRougangranuleinthetreatmentofnonalcoholicfattyliverdiseaseYuYang，QianLiqi，HouPeng，WuBing，LiSuna，RenJintao(TheFirstAfiliatedHospitaloftheGeneralHospitalofPLA，Beijing100048，China)Abstract：ObjectiveItistoobservetheclinicalcurativeeffectofHuazhiRougangranule(HZRGG)inthetreat

4、mentofnonalcoholicfattyliverdisease(NAFLD)．Methods60patientswithNAFLDwererandomlydivideintotwogroups．30casesincontrolgroupweretreatedwithoral—takenmilkthistlemegluminewhile30casesintreatmentgroupweretreatedwithHZRGG，andallpatientsweretreatedfor12weeks．Thesymptomscore，serumliverenzyme，bl

5、oodlipid，bodymassindexandliverultrasounddivisionofthetwogroupsbeforeandaftertreatmentwerecompared．ResultsThetotaleffectiverateoftreatmentgroupwas87％whilethecontrolgroupwas67％，therewassignificantdifference(P<0．05)．Thesymptomsscore，bodymassindex，bloodlipidandliverultrasounddivisionofthetr

6、eatmentgroupweresignificantlybetterthanthatofcontrolgroup(P<0．05)．Theliverfunctionsofeachgroupwereimprovedafiertreatment；therewasnosignificantdiferencebetweenthetwogroups(P>0．05)．ConclusionHZRGGhasaneffectivecurativeeffectonthetreatmentofNAFLD，thoughtitsmechanismisyettobefurtherstudied．

7、Keywords：nonalcoholicfattyliverdisease；HuazhiRougangranule；milkthistlemeglumine非酒精性脂肪性肝病(NAFLD)是一种与胰岛素抵抗脱落3例，实际完成60例。人选患者均符合2010年中华医(IR)和遗传易感密切相关的代谢应激性肝脏损伤，包括非酒学会肝病学分会脂肪肝和酒精性肝病学组制订的《非酒精性精性单纯性脂肪肝(NAFL)、非酒精性脂肪性肝炎(NASH)及脂肪性肝病诊疗指南》，近1个月来未服用调脂护肝药物，NASH相关肝硬化”。随着肥胖和代谢综合征的全球化流均无嗜酒史，并除外